Experienced in Diabetic Neuropathy

Dr. Nayvis Iglesias

Family Medicine
Nextlevel Complete Family Care Inc
10450 Nw 33rd St, Unit 205, 
Doral, FL 
Accepting New Patients
Experienced in Diabetic Neuropathy
Nextlevel Complete Family Care Inc
10450 Nw 33rd St, Unit 205, 
Doral, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nayvis Iglesias is a primary care provider, practicing in Family Medicine in Doral, Florida. Dr. Iglesias is rated as an Experienced provider by MediFind in the treatment of Diabetic Neuropathy. Her top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young. Dr. Iglesias is currently accepting new patients.

Her clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Family Medicine
Licenses
Family Medicine in FL
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 9 Less Insurance Carriers -

Locations

NEXTLEVEL COMPLETE FAMILY CARE INC
10450 Nw 33rd St, Unit 205, Doral, FL 33172

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Drug
Study Drug: VT-1161
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Advanced in Diabetic Neuropathy
Dr. Anibal J. Loza
Family Medicine
Advanced in Diabetic Neuropathy
Dr. Anibal J. Loza
Family Medicine

Holy Cross Hospital Inc

4725 N Federal Hwy, Suite 502, 
Fort Lauderdale, FL 
 (31.5 miles away)
954-542-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anibal Loza is a primary care provider, practicing in Family Medicine in Fort Lauderdale, Florida. Dr. Loza is rated as a Distinguished provider by MediFind in the treatment of Diabetic Neuropathy. His top areas of expertise are Opioid Induced Constipation, Magnesium Deficiency, Low Blood Pressure, Hip Replacement, and Bone Graft. Dr. Loza is currently accepting new patients.

Advanced in Diabetic Neuropathy
Dr. William M. Demarchi
Family Medicine | Internal Medicine
Advanced in Diabetic Neuropathy
Dr. William M. Demarchi
Family Medicine | Internal Medicine
9878 Clint Moore Road, Suite 202, 
Boca Raton, FL 
 (44.1 miles away)
561-451-2454
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

William Demarchi is a primary care provider, practicing in Family Medicine and Internal Medicine in Boca Raton, Florida. Dr. Demarchi is rated as an Advanced provider by MediFind in the treatment of Diabetic Neuropathy. His top areas of expertise are Hypertensive Heart Disease, Nephrosclerosis, Renovascular Hypertension, and Pediatric Myocarditis. Dr. Demarchi is currently accepting new patients.

Advanced in Diabetic Neuropathy
Dr. Wayne N. Evancho
Family Medicine
Advanced in Diabetic Neuropathy
Dr. Wayne N. Evancho
Family Medicine
1380 Ne Miami Gardens Dr, Suite 285, 
North Miami Beach, FL 
 (16.0 miles away)
305-944-8777
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Wayne Evancho is a primary care provider, practicing in Family Medicine in North Miami Beach, Florida. Dr. Evancho is rated as an Advanced provider by MediFind in the treatment of Diabetic Neuropathy. His top areas of expertise are Dementia, Type 2 Diabetes (T2D), Alzheimer's Disease, and Familial Hypertension. Dr. Evancho is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Iglesias's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile